BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1503 related articles for article (PubMed ID: 24140396)

  • 21. Trends in pre-liver transplant screening for cholangiocarcinoma among patients with primary sclerosing cholangitis.
    Trilianos P; Selaru F; Li Z; Gurakar A
    Digestion; 2014; 89(2):165-73. PubMed ID: 24577150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transplantation for hilar cholangiocarcinoma.
    Heimbach JK; Haddock MG; Alberts SR; Nyberg SL; Ishitani MB; Rosen CB; Gores GJ
    Liver Transpl; 2004 Oct; 10(10 Suppl 2):S65-8. PubMed ID: 15382214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis.
    Grimsrud MM; Folseraas T
    Liver Int; 2019 Dec; 39(12):2230-2237. PubMed ID: 31216595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholangiocarcinoma: modern advances in understanding a deadly old disease.
    Malhi H; Gores GJ
    J Hepatol; 2006 Dec; 45(6):856-67. PubMed ID: 17030071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
    Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
    J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of serial versus isolated biliary fluorescence in situ hybridization (FISH) polysomy in primary sclerosing cholangitis.
    Quinn KP; Tabibian JH; Lindor KD
    Scand J Gastroenterol; 2017 Apr; 52(4):377-381. PubMed ID: 27908204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
    Xu L; Wang P; Zhang W; Li W; Liu T; Che X
    Front Oncol; 2021; 11():757498. PubMed ID: 34660327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
    Sapisochin G; Ivanics T; Heimbach J
    Hepatology; 2022 Feb; 75(2):455-472. PubMed ID: 34859465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholangiocarcinoma: Diagnosis and Management.
    Buckholz AP; Brown RS
    Clin Liver Dis; 2020 Aug; 24(3):421-436. PubMed ID: 32620281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis.
    Villard C; Friis-Liby I; Rorsman F; Said K; Warnqvist A; Cornillet M; Kechagias S; Nyhlin N; Werner M; Janczewska I; Hagström T; Nilsson E; Bergquist A
    J Hepatol; 2023 Mar; 78(3):604-613. PubMed ID: 36410555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis.
    Kamp EJ; Dinjens WN; Doukas M; van Marion R; Verheij J; Ponsioen CY; Bruno MJ; Groot Koerkamp B; Trivedi PJ; Peppelenbosch MP; de Vries AC
    J Pathol; 2022 Nov; 258(3):227-235. PubMed ID: 35897137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the clinical diagnosis and therapy of cholangiocarcinoma.
    Yao D; Kunam VK; Li X
    J Int Med Res; 2014 Feb; 42(1):3-16. PubMed ID: 24366497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholangiocarcinoma.
    Razumilava N; Gores GJ
    Lancet; 2014 Jun; 383(9935):2168-79. PubMed ID: 24581682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholangiocarcinoma.
    Patel T
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jan; 3(1):33-42. PubMed ID: 16397610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
    Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
    J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
    Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S
    Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.